Mark W. Surber
Gründer bei Avalyn Pharma, Inc.
Profil
Mark W.
Surber is the founder of Avalyn Pharma, Inc. where he holds the title of Director & Chief Scientific Officer since 2011.
Dr. Surber is also the founder of MPEX Pharmaceuticals, Inc. He previously worked as a Principal at IGEN International, Inc. Dr. Surber received his undergraduate degree from The California State University and his doctorate from the University of Illinois.
Aktive Positionen von Mark W. Surber
| Unternehmen | Position | Beginn |
|---|---|---|
Avalyn Pharma, Inc.
 Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Gründer | 01.01.2011 |
Ehemalige bekannte Positionen von Mark W. Surber
| Unternehmen | Position | Ende |
|---|---|---|
IGEN International, Inc.
 IGEN International, Inc. Medical SpecialtiesHealth Technology IGEN International, Inc. develops and markets biological testing systems that incorporate its proprietary electrochemiluminescence technology for used in drug discovery, diagnostic products development as well as food and environmental safety testing. The company was founded in 1982 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Gründer | - |
Ausbildung von Mark W. Surber
| University of Illinois | Doctorate Degree |
| The California State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
MPEX Pharmaceuticals, Inc.
MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Commercial Services |
IGEN International, Inc.
IGEN International, Inc. Medical SpecialtiesHealth Technology IGEN International, Inc. develops and markets biological testing systems that incorporate its proprietary electrochemiluminescence technology for used in drug discovery, diagnostic products development as well as food and environmental safety testing. The company was founded in 1982 and is headquartered in Gaithersburg, MD. | Health Technology |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Health Technology |
